André Lieber

University of Washington — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

61h-index12.8kcitations326works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(216), CAR-T cell therapy research(95), Viral Infectious Diseases and Gene Expression in Insects(76), RNA Interference and Gene Delivery(69), CRISPR and Genetic Engineering(63)

Publications325 total

DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid Tumors
2026Open Access
Molecular analysis of blood-associated pathogens in common ravens (Corvus corax) from Germany
Parasitology Research·2025Open Access
Universal solid tumor therapy with CD5-deleted, DSG2-directed CAR-T cells.
Journal of Clinical Oncology·2025
In vivo HSC transduction in humanized mice mediated by novel capsid-modified HDAd vectors
Molecular Therapy — Methods & Clinical Development·2025· 2 citedOpen Access
Resolving the chromatin impact of mosaic variants with targeted Fiber-seq
Genome Research·2024· 8 citedOpen Access
Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice
Molecular Therapy·2024· 12 citedOpen Access
In vitro and in vivo expansion of CD33/HBG promoter-edited HSPCs with Mylotarg
Molecular Therapy — Methods & Clinical Development·2024· 2 citedOpen Access
Auto-expansion of in vivo HDAd-transduced hematopoietic stem cells by constitutive expression of tHMGA2
Molecular Therapy — Methods & Clinical Development·2024· 2 citedOpen Access
Resolving the chromatin impact of mosaic variants with targeted Fiber-seq
2024· 2 citedOpen Access
A simplified G-CSF–free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model
Blood Advances·2024· 10 citedOpen Access
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
Cancer Biology & Therapy·2024· 9 citedOpen Access
Prospects and challenges of in vivo hematopoietic stem cell genome editing for hemoglobinopathies
Molecular Therapy·2023· 5 citedOpen Access
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
page 1 of 17Next →

Frequent Co-authors

Dmitry M. Shayakhmetov(13), Shaoheng Ni(13), Zong-Yi Li(10), Mark A. Kay(10), Robert Strauss(8), Anuj Gaggar(6), Sebastian Tuve(6), Hongjie Wang(5), Akseli Hemminki(4), Zongyi Li(4), Pavel Sova(4), Daniel Stone(4), Qinghua Feng(4), Roma Yumul(4), Ines Beyer(3), Pascal Fender(3), C Y He(3), Thalia Papayannopoulou(3), James D. Perkins(3), Steve R. Roffler(3)